Deregulation of the activin/follistatin system in hepatocarcinogenesis
about
Activins and activin antagonists in hepatocellular carcinomaRNA-Seq profiling reveals novel hepatic gene expression pattern in aflatoxin B1 treated ratsHigh circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver diseaseIdentification of proteins involved in neural progenitor cell targeting of gliomas.Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.Cancer metastasis: enactment of the script for human reproductive drama.Nucleolar follistatin promotes cancer cell survival under glucose-deprived conditions through inhibiting cellular rRNA synthesis.Activins and follistatins: Emerging roles in liver physiology and cancerInhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.Chemopreventive effect of selenium and Chinese medicinal herbs on N-nitrosobis(2-oxopropyl)amine-induced hepatocellular carcinoma in Syrian hamsters.Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1Clinical and Therapeutic Implications of Follistatin in Solid Tumours.Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report.The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy.Follistatin as potential therapeutic target in prostate cancer.A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).AhR-mediated changes in global gene expression in rat liver progenitor cells.Prognotic impact of serum follistatin in patients with hepatocellular carcinoma.The effect of oncoprotein v-erbA on thyroid hormone-regulated genes in hepatocytes and their potential role in hepatocellular carcinoma.Effects of chronic hepatitis C genotype 1 and 4 on serum activins and follistatin in treatment naïve patients and their correlations with interleukin-6, tumour necrosis factor-α, viral load and liver damage.Transcriptional profile of Rous Sarcoma Virus transformed chicken embryo fibroblasts reveals new signaling targets of viral-src.Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies.Over-Expression of Activin-βC Is Associated with Murine and Human Prostate Disease.Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma.
P2860
Q24646221-902B3AF6-11F6-47A4-B9D3-1050D7092EDBQ27324185-6B1CE100-86AA-4AC0-98AB-803CD1477282Q27853357-F4CBC670-E04D-4898-B783-99E3E0A8604EQ33353052-0816CD33-758C-497C-A34F-483423F9996EQ33475160-C78F127D-93B0-4F6D-ADA3-B2516E3E454EQ33509293-C763AC94-6251-4D47-B22F-FA82FC35901CQ33629970-CE236F05-9BE9-4184-8014-FB4EFB9848DEQ34299252-167319AC-8E83-4CB5-8E35-75AE2E10001CQ34391497-79ADE824-4C03-44B5-B4F9-58D398074F48Q34806721-A13ACD5F-447E-447E-9D0C-41FE418D535BQ35563500-46F54D85-3C75-4C26-9FA2-89D6F692BC0CQ36059811-7873CADC-6C60-4371-8BA3-0E2DCC24E7C8Q36451785-13C807D2-64FC-47DD-B291-A7EE639CA020Q36737425-914490B4-EAA6-4B1A-8F18-3D8E2EAE54C6Q37142538-EEC5C7E0-27CC-4BE0-93B6-B54ACB8D58BCQ37569979-2F762838-0AAD-44A5-BC7F-725AE4A7857AQ37715878-3D833F13-A4B2-4A13-B914-92118975D7EFQ37780777-11BC2695-10E6-4FC5-B3E5-EDC0761B4C1BQ38086102-B5052995-FF51-439A-87E1-1C3E06D62B6CQ38387061-5A7A6A73-A2AA-4106-93CF-9CE5C24B1320Q38493790-2FE932A8-6235-4889-BCE9-42CE277B0CDAQ39463161-97D7BE67-D168-4792-B612-B84D9AD9B444Q39689207-4C819AE0-9994-49F5-A552-7C6A95882A81Q42212782-632FAF94-5C3F-4027-8665-BEAAC0B5CEFDQ43156526-9E1621F1-AD26-4659-8CBC-D439E0D4F669Q45330911-B82A8763-B00F-477D-B67C-1E15F4FAF431Q50459543-E0773676-0416-4265-8A60-AE38470C7F4DQ53794062-8C654A82-0E87-4BCE-B89E-A46585DAC02A
P2860
Deregulation of the activin/follistatin system in hepatocarcinogenesis
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@ast
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@en
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@nl
type
label
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@ast
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@en
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@nl
prefLabel
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@ast
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@en
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@nl
P2093
P50
P1476
Deregulation of the activin/follistatin system in hepatocarcinogenesis
@en
P2093
Annemarie Losert
Barbara Peter-Vörösmarty
Bettina Grasl-Kraupp
Claudia Drucker
Doris Macheiner
Natascha Erlach
Nigel P Groome
Rolf Schulte-Hermann
Wolfgang J Schneider
Wolfram Parzefall
P304
P356
10.1016/J.JHEP.2006.06.014
P407
P577
2006-07-28T00:00:00Z